PHT1-13 Antibody

What is PHT1-13 and what biological role does it play?

PHT1-13 is a member of the PHT1 family of high-affinity transporters responsible for the uptake of inorganic phosphate from the extracellular environment. While PHT1 in humans (also known as solute carrier family 15 member 4 or SLC15A4) functions as a histidine/oligopeptide transporter involved in innate immune responses, PHT1-13 specifically is a phosphate transporter found in rice (Oryza sativa). In humans, the PHT1 protein consists of 577 amino acid residues, is localized to the lysosomes of cells, and is highly expressed in skeletal muscle . The protein plays crucial roles in Toll-like receptor (TLR) signaling pathways and contributes to type I interferon production through interaction with the adaptor protein TASL .

How does PHT1-13 differ from other members of the PHT1 family?

PHT1-13 differs from other PHT1 family members primarily in its substrate specificity and expression patterns. While all PHT1 family transporters belong to the major facilitator superfamily (MFS) and share a common structural fold comprising twelve transmembrane helices with intracellular amino- and carboxy-termini, they have distinct expression profiles, substrates, and biological functions . In contrast to human PHT1 (SLC15A4) that functions as a histidine/oligopeptide transporter involved in immune responses, PHT1-13 in plants specializes in high-affinity phosphate transport, which is critical for plant nutrition and growth.

What are the common applications of PHT1-13 antibody in research?

PHT1-13 antibodies are primarily used for antigen-specific immunodetection in biological samples. Common applications include:

• Western blotting for protein expression analysis

• Immunohistochemistry for localization studies

• Immunoprecipitation for protein-protein interaction studies

• Flow cytometry for cell-specific expression analysis

These antibodies are valuable tools for studying phosphate transport mechanisms in plant systems and can help understand nutrient acquisition pathways in crops like rice . In human systems, similar antibodies against PHT1 (SLC15A4) are used to study innate immune responses and their role in autoimmune diseases like systemic lupus erythematosus (SLE) .

What are the optimal conditions for using PHT1-13 antibody in Western blotting?

For optimal Western blot results with PHT1-13 antibody, follow these methodological guidelines:

• Sample preparation: Extract proteins using phosphate-free buffers to preserve native conformation of phosphate transporters.

• Denaturation: Use moderate heat (70°C for 10 minutes) rather than boiling to prevent aggregation of membrane proteins.

• Blocking: Employ 5% non-fat dry milk in TBST (Tris-buffered saline with 0.1% Tween-20) for 1 hour at room temperature.

• Primary antibody incubation: Dilute PHT1-13 antibody 1:1000 to 1:5000 in TBST with 1% BSA and incubate overnight at 4°C.

• Detection: For enhanced sensitivity, use fluorescent secondary antibodies rather than HRP-conjugated antibodies.

Optimal membrane transfer conditions include using PVDF membranes and semi-dry transfer at 15V for 30 minutes for these transmembrane proteins . Always validate antibody specificity using appropriate positive and negative controls, including PHT1-13 knockout/knockdown samples when available.

How can I minimize non-specific binding when using PHT1-13 antibody?

Non-specific binding can significantly impact experimental results. To minimize this issue with PHT1-13 antibody:

• Optimize antibody concentration: Titrate antibody concentration to determine the optimal dilution that maximizes specific signal while minimizing background.

• Enhance blocking protocol: Use a combination of 3-5% BSA with 0.5% casein to effectively block hydrophobic and charged surface patches that contribute to non-specific binding.

• Add detergents: Include 0.1-0.3% Triton X-100 or 0.05% Tween-20 in washing and antibody incubation steps.

• Pre-adsorb the antibody: Incubate diluted antibody with negative control lysates to remove cross-reactive antibodies.

• Consider the impact of surface patches: As demonstrated in antibody research, hydrophobic patches in the complementarity-determining regions (CDRs) can significantly contribute to non-specific binding with affinities as high as 1 μM .

For quantitative analysis, compare hydrophobic versus total charged patch areas to distinguish between high-affinity (KD ~1 μM) and low-affinity (KD >10 μM) binding . This approach helps predict and mitigate non-specific interactions.

What cross-reactivity concerns should I be aware of when using PHT1-13 antibody?

When working with PHT1-13 antibody, researchers should be aware of several potential cross-reactivity concerns:

• Related PHT family members: Due to sequence homology among PHT1 family transporters, antibodies may cross-react with other PHT1 isoforms. For example, rice has 13 PHT1 family members with varying degrees of similarity.

• Orthologous proteins across species: The antibody may recognize homologous phosphate transporters in other plant species, which can be either advantageous or problematic depending on your research question.

• Other transmembrane transporters: Other members of the major facilitator superfamily with similar structural motifs may produce false positive signals.

To address these concerns, implement these methodological approaches:

• Perform validation with recombinant proteins for each suspected cross-reactive target

• Use epitope mapping to identify the specific binding region

• Employ genetic knockouts or knockdowns as negative controls

• When studying multiple species, validate cross-reactivity for each target organism

How can I use PHT1-13 antibody to study PHT1-TASL signaling interactions in autoimmune disease models?

For investigating PHT1-TASL signaling interactions in autoimmune disease models, implement this methodological framework:

• Co-immunoprecipitation studies: Use PHT1 antibodies to pull down protein complexes and detect TASL with specific anti-TASL antibodies. Based on structural insights, focus on the first 16 N-terminal TASL residues that form a helical structure binding to the central cavity of PHT1 .

• Proximity ligation assays (PLA): Apply this technique to visualize and quantify PHT1-TASL interactions in situ at subcellular resolution.

• FRET-based interaction studies: Develop fluorescently labeled antibody fragments to monitor dynamic PHT1-TASL interactions in live cells.

• Conformational state analysis: Use conformation-specific antibodies to distinguish between outward-open and inward-open conformations of PHT1, as these conformational states are critical for TASL recruitment and signaling .

• Disease model correlation: Correlate interaction patterns with type I interferon production via IRF5 and disease progression markers in SLE or other autoimmune disease models.

This approach can provide valuable insights into how persistent stimulation of this signaling pathway contributes to SLE pathogenesis and may identify potential therapeutic intervention points .

What structural insights can be gained from using PHT1-13 antibody in Cryo-EM studies?

PHT1-13 antibodies can significantly enhance Cryo-EM structural studies through these methodological approaches:

• Fab-assisted particle visualization: Antibody fragments (Fabs) derived from PHT1-13 antibodies can serve as fiducial markers to improve particle alignment and orientation determination during image processing.

• Conformational stabilization: By binding to specific epitopes, antibodies can stabilize particular conformational states of PHT1-13, enabling structural characterization of transient states that would otherwise be difficult to capture.

• Structure-function correlation: Compare structures stabilized in outward-open versus inward-open conformations to understand the molecular mechanism of phosphate transport and TASL recruitment .

• Epitope mapping: By analyzing the binding interface between PHT1-13 and the antibody, researchers can identify functional domains and interaction surfaces that may be critical for transporter function.

• Comparative structural analysis: Use structural insights to compare PHT1-13 with other members of the major facilitator superfamily to identify conserved and unique structural features.

Recent Cryo-EM studies have already provided valuable insights into the structure of human PHT1 (SLC15A4) stabilized in the outward-open conformation, offering a foundation for understanding molecular mechanisms of transporter function and signaling .

How can I address poor signal-to-noise ratio when using PHT1-13 antibody in immunofluorescence studies?

Poor signal-to-noise ratio is a common challenge in immunofluorescence studies. To improve results with PHT1-13 antibody:

• Fixation optimization: Compare different fixation methods (4% paraformaldehyde, methanol, or glutaraldehyde) to determine which best preserves epitope accessibility while maintaining cellular structure.

• Epitope retrieval: Implement antigen retrieval methods such as heat-induced epitope retrieval (HIER) or proteolytic-induced epitope retrieval (PIER) to unmask epitopes potentially hidden during fixation.

• Antibody concentration gradient: Test a dilution series (1:100 to 1:2000) to identify the optimal antibody concentration that maximizes specific signal while minimizing background.

• Signal amplification systems: Consider tyramide signal amplification (TSA) or quantum dot-conjugated secondary antibodies for weak signals.

• Confocal microscopy settings: Optimize pinhole size, detector gain, and laser power to enhance signal discrimination.

• Surface property considerations: Be aware that the balance between hydrophobic patches and charged surface areas on antibodies significantly affects their binding characteristics and potential for non-specific interactions .

Creating a systematic optimization matrix that varies these parameters can help identify the ideal conditions for specific PHT1-13 detection in your specific cell type or tissue.

What are the best approaches for validating PHT1-13 antibody specificity?

Rigorous validation of antibody specificity is essential for reliable experimental results. For PHT1-13 antibody, implement these methodological approaches:

• Genetic validation:

  • Use CRISPR/Cas9-mediated knockout of PHT1-13

  • Apply siRNA or shRNA-mediated knockdown

  • Compare signals between wild-type and modified samples

• Recombinant protein controls:

  • Test antibody against purified recombinant PHT1-13 protein

  • Include closely related PHT family members as specificity controls

  • Perform peptide competition assays using the immunizing peptide

• Orthogonal detection methods:

  • Compare results with multiple antibodies targeting different epitopes

  • Correlate protein detection with mRNA expression using qRT-PCR

  • Verify subcellular localization patterns match expected distribution

• Cross-species reactivity assessment:

  • Test reactivity across relevant plant species if studying plant PHT1-13

  • Evaluate specificity against human PHT1 (SLC15A4) if studying the human homolog

• Multiple application validation:

  • Confirm consistent results across different techniques (Western blot, IP, IF, IHC)

  • Document molecular weight, localization, and expression patterns

This comprehensive validation approach ensures reliable results and prevents misinterpretation due to antibody cross-reactivity.

How does the Fab region of PHT1-13 antibody impact its internalization and intracellular trafficking?

The Fab region of antibodies, including PHT1-13 antibody, can significantly impact internalization and intracellular trafficking through several mechanisms:

• Internalization kinetics: Research comparing full-size IgG with Fc fragments has demonstrated that the presence of Fab regions can impair binding to receptors in cellular contexts, even when cell-free assays show no difference . For PHT1-13 antibody applications, this suggests that Fab-mediated steric hindrance may alter internalization rates.

• Intracellular accumulation: Studies have shown that Fc fragments accumulate more efficiently in cells compared to full-size IgG counterparts. In FcRn-expressing cells, Fc fragments demonstrated enhanced intracellular retention compared to full-sized IgG .

• Receptor blocking efficiency: When blocking cellular receptors is desired, the absence of Fab regions leads to more efficient receptor antagonism both in vitro and in vivo .

• Surface property considerations: The balance of hydrophobic patches versus charged surface areas on the Fab region influences non-specific interactions and potential off-target binding .

For optimal experimental design when studying membrane proteins like PHT1-13, researchers should consider using Fab fragments or single-chain variable fragments (scFvs) to minimize steric hindrance while maintaining target specificity. Alternatively, carefully selecting antibody clones with exposed paratopes that maintain accessibility in the cellular environment can improve internalization efficiency.

What considerations should be made when designing experiments to study PHT1-13 phosphate transport activity using antibodies?

When designing experiments to study PHT1-13 phosphate transport activity using antibodies, consider these methodological approaches:

• Functional vs. inhibitory antibodies:

  • Select non-inhibitory antibodies for transport activity monitoring

  • Develop function-blocking antibodies when inhibition studies are required

  • Characterize epitope location relative to the transporter's functional domains

• Real-time transport assays:

  • Use radioisotope (³²P or ³³P) uptake assays with antibody pre-treatment

  • Implement fluorescent phosphate analogs for dynamic visualization

  • Develop antibody-based FRET biosensors to monitor conformational changes during transport

• Structure-function correlation:

  • Target antibodies to specific conformational states (inward-open vs. outward-open)

  • Consider that PHT1 transporters share a common fold with twelve transmembrane helices and pseudosymmetry between structural motifs

  • Use antibodies to stabilize specific transport cycle intermediates

• Experimental controls:

  • Include non-specific IgG controls matched for isotype

  • Employ competitive inhibitors of phosphate transport as positive controls

  • Design transport-deficient mutants as reference standards

• Physiologically relevant conditions:

  • Maintain appropriate pH gradients for proton-coupled transport

  • Consider ionic strength effects on antibody binding and transport activity

  • Use relevant cellular models expressing native levels of transporters

This comprehensive approach will yield more reliable insights into PHT1-13 transport mechanisms while minimizing artifacts from antibody interference.

How should I quantitatively analyze immunolocalization data for PHT1-13 in plant root tissues?

For rigorous quantitative analysis of PHT1-13 immunolocalization in plant root tissues, follow these methodological guidelines:

This standardized approach ensures reproducible and statistically sound interpretation of PHT1-13 localization patterns in different plant tissues and under varying environmental conditions.

What contradictions exist in the current understanding of PHT1 function, and how can antibody-based approaches help resolve them?

Several contradictions exist in our current understanding of PHT1 function, and antibody-based approaches offer powerful methods to resolve these discrepancies:

• Dual transport vs. signaling functions:

  • Contradiction: Whether PHT1 acts primarily as a transporter or as a signaling receptor remains controversial.

  • Resolution approach: Develop conformation-specific antibodies that distinguish between transport-active and signaling-active states of PHT1. Research has shown PHT1 can act as a receptor by recruiting the adaptor protein TASL, leading to type I interferon production via IRF5 .

• Substrate specificity overlap:

  • Contradiction: The extent to which PHT1 transporters discriminate between phosphate, histidine, and oligopeptides remains unclear.

  • Resolution approach: Design antibodies that target the substrate-binding pocket and use them in competitive binding studies with different substrates to map specificity determinants.

• Subcellular localization discrepancies:

  • Contradiction: Reports of PHT1 localization vary between plasma membrane, lysosomes, and other compartments.

  • Resolution approach: Implement super-resolution microscopy with organelle-specific markers and PHT1 antibodies to resolve subcellular distribution. Current research indicates human PHT1 (SLC15A4) is localized to lysosomes .

• Regulatory mechanisms:

  • Contradiction: The relative importance of transcriptional vs. post-translational regulation remains debated.

  • Resolution approach: Combine phospho-specific antibodies with total PHT1 antibodies to monitor phosphorylation states under different conditions, correlating with functional activity.

• TASL binding mechanism:

  • Contradiction: The precise molecular basis for TASL recruitment remains incompletely understood.

  • Resolution approach: Develop antibodies targeting the first 16 N-terminal TASL residues that form a helical structure binding to PHT1's central cavity in the inward-open conformation .

These antibody-based approaches, combined with genetic and biochemical methods, will help resolve current contradictions and advance our understanding of this important protein family.

How can PHT1-13 antibody be used in studying plant stress responses and nutrient acquisition strategies?

PHT1-13 antibody provides valuable tools for investigating plant stress responses and nutrient acquisition strategies through these methodological approaches:

• Phosphate deficiency responses:

  • Monitor dynamic changes in PHT1-13 expression and localization during phosphate starvation

  • Compare cellular distribution patterns between phosphate-sufficient and -deficient conditions

  • Correlate protein levels with transcriptional changes using complementary RNA analysis

• Root architecture adaptation:

  • Analyze PHT1-13 distribution across different root zones during architectural remodeling

  • Examine cell type-specific expression patterns in response to heterogeneous phosphate distribution

  • Investigate the relationship between PHT1-13 localization and root hair development

• Mycorrhizal symbiosis studies:

  • Compare PHT1-13 expression between mycorrhizal and non-mycorrhizal roots

  • Examine localization at fungal-plant interfaces

  • Investigate potential reprogramming of phosphate transport systems during symbiosis

• Stress signaling integration:

  • Analyze PHT1-13 expression under combined nutrient and abiotic stress conditions

  • Investigate potential post-translational modifications in response to stress signals

  • Examine co-localization with stress-responsive signaling components

• Crop improvement applications:

  • Compare PHT1-13 expression and localization between efficient and inefficient phosphate-utilizing crop varieties

  • Use antibody-based screening to identify germplasm with optimized phosphate transport systems

  • Validate transgenic modifications aimed at improving phosphate acquisition

These applications provide critical insights into plant nutrient acquisition mechanisms and support the development of crops with enhanced nutrient use efficiency.

What potential does PHT1-13 antibody hold for developing immunotherapeutic approaches for autoimmune disorders?

The development of PHT1-13 antibody-based therapeutics for autoimmune disorders represents an emerging research direction with significant potential:

• Targeting PHT1-TASL interaction:

  • Design antibodies that specifically disrupt the interaction between PHT1 and TASL, which could inhibit type I interferon production via IRF5

  • Focus on the critical binding interface where the first 16 N-terminal TASL residues form a helical structure that binds in PHT1's central cavity

  • Develop screening platforms using PHT1-13 antibodies to identify small molecule disruptors of this interaction

• Modulating PHT1 conformational states:

  • Create conformation-specific antibodies that stabilize PHT1 in states unfavorable for TASL recruitment

  • Use structural insights from Cryo-EM studies of PHT1 in outward-open conformation to guide antibody design

  • Develop antibody fragments or mimetics that can access the central cavity of PHT1

• Therapeutic antibody optimization:

  • Apply insights about antibody surface properties to optimize therapeutic antibodies against PHT1

  • Consider the critical balance between hydrophobic patches and charged surface areas to minimize non-specific binding

  • Compare Fab-containing versus Fc-only constructs for optimal cellular uptake and target engagement

• Biomarker development:

  • Establish PHT1 expression or activation as a potential biomarker for SLE and other autoimmune conditions

  • Develop immunoassays to monitor PHT1-TASL interaction status in clinical samples

  • Create diagnostic tools to stratify patients based on PHT1 pathway activation

• Delivery optimization:

  • Consider that Fc fragments may demonstrate enhanced intracellular accumulation compared to full-size IgG counterparts

  • Develop strategies to enhance antibody delivery to lysosomes where PHT1 is primarily localized